• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• News

• News
• Features
• NICE newsletters and alerts
• Events
• Media centre
• NICE annual conference
• Guidance in Focus
• Podcasts
• Videocasts
• Meetings held in public

2006/018 100th NICE technology appraisal guidance offers new hope for people with colon cancer

The National Institute for Health and Clinical Excellence (NICE) has today (26 April 2006) published its 100^th technology appraisal guidance. The guidance to the NHS in England and Wales on the use of capecitabine and oxaliplatin for the adjuvant treatment of patients with stage III (Dukes' C)* colon cancer following surgery for the condition, recommends that the drugs should be considered as options for the adjuvant treatment of patients as follows:

• capecitabine as monotherapy
• oxaliplatin in combination with 5-fluorouracil and folinic acid.

2006/018 100th NICE technology appraisal guidance offers new hope for people with colon cancer 26 April 2006 (139.4Kb 01min 48sec @ 28.8Kbps)

Adobe Acrobat reader required.

This page was last updated: 03 August 2007